Posted: 7 November 2025
The Board of BioMelbourne Network acknowledges the resignation of CEO Karen Parr, effective as of 14 November 2025. We thank Karen for her service.
Reflecting on her time with the Network, Karen said: ‘It has been an honour to serve this passionate sector, and I wish the organisation and its members continued success in advancing Victoria’s health technologies sector.’
To ensure continuity, Operations Manager Vicky Jones will step into the role of Acting CEO. Vicky has been a key part of the organisation since 2014 and brings strong operational and sector knowledge. All current programs, events and strategic initiatives will continue as planned.
The Board will now undertake a review of the organisation’s leadership requirements and consider the best structure to support the next phase of BioMelbourne Network’s work.
Our priorities remain unchanged: delivering value for members, advocating for the growth of Victoria’s health technologies sector, and strengthening industry-government alignment. The organisation is well-positioned for its next chapter, and the Board is focused on stability and continuity.
On behalf of the BioMelbourne Network Board,
Dr Emma Ball, PhD MBA GAICD
Chair
-END-
Contact:
Claudia Loeber-Raab, Communications and Marketing Manager
Email: [email protected] | Mob 0425 785 143
About BioMelbourne Network
BioMelbourne Network is the peak body in the Victorian health technologies industry, driving engagement and growth in innovation, commercialisation and manufacturing through local and international networks. Since 2001, it has been actively fostering and growing an innovative, globally-competitive sector and transforming its Network as well as the broader Victorian ecosystem. BioMelbourne Network proudly represents >200 companies and 6000+ people from local, national and international companies, as well as the broader Victorian health technologies sector.
Representing the entire health technologies, R&D ecosystem, our members traverse bench to bedside and are experts in their respective fields, including biotherapeutics (medicines, therapies and vaccines) and medical technologies (devices, diagnostics and digital health), and broader health technology innovation.
